Syndax Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview

Syndax Pharmaceuticals

31/10/2023 23:55

* Syndax Pharmaceuticals Inc  SNDX.OQ   SNDX.O  is expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Syndax
Pharmaceuticals
Inc is for a loss of 79 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is $36​, above​ its last closing price
of $14.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.73       -0.73      -0.64     Beat    12.6
 Mar. 31 2023  -0.60       -0.60      -0.59     Beat    1
 Dec. 31 2022  -0.65       -0.65      -0.62     Beat    4.4​
 Sep. 30 2022  -0.64       -0.63      -0.58     Beat    8.7
 ​​Jun.        -0.66       -0.64      -0.62     Beat    2.6
 30 2022                                                
 Mar. 31 2022  -0.63       -0.63      -0.63     Met     0.8​
 Dec. 31 2021  0.23        0.28       1.81      Beat    550.3
 Sep. 30 2021  0.01        -0.23      -0.40     Missed  -72.7
 This summary was machine generated October 31 at 23:54 GMT.  All
figures in US dollars  unless otherwise stated